Napcon0.025%+0.3%

Napcon ophthalmic solution is an over-the-counter (OTC) combination eye drop used for the temporary relief of eye redness and itching caused by minor eye irritations and allergic conjunctivitis.

Established / OTC-labeled uses

• Temporary relief of redness of the eye due to minor eye irritations (e.g., dust, smoke, swimming, contact lens wear).
• Temporary relief of itching and redness associated with allergic conjunctivitis (e.g., due to pollen, ragweed, grass, animal hair or dander).

Not indicated for

• Bacterial, viral, or fungal eye infections.
• Glaucoma, eye pain, or serious ocular conditions requiring prescription treatment.

Napcon is intended only for short-term, symptomatic relief and is not a treatment for the underlying cause of eye redness or allergy.

Naphazoline + Pheniramine ophthalmic solution typically contains Naphazoline Hydrochloride 0.025% w/v as the decongestant component and Pheniramine Maleate 0.3% w/v as the antihistamine component, along with ophthalmic-grade excipients and a preservative (commonly benzalkonium chloride) in a sterile isotonic buffered vehicle.

Exact strengths and excipients may vary slightly by manufacturer; the product label of the dispensed brand should always be checked for the precise composition of Naphazoline + Pheniramine.

Napcon is a fixed-dose combination ophthalmic (eye) preparation that pairs a topical alpha-adrenergic decongestant (naphazoline) with a first-generation H1-antihistamine (pheniramine). It is widely available as an OTC eye drop for the short-term symptomatic relief of red, itchy, watery eyes caused by allergens or minor irritants.

By combining a vasoconstrictor with an antihistamine, Napcon addresses both the visible redness (via constriction of conjunctival blood vessels) and the itching/allergic component (via blockade of histamine H1-receptors) of allergic and irritative conjunctivitis in a single formulation.

Ophthalmic decongestant–antihistamine combination; Napcon belongs to the class of topical imidazoline alpha-adrenergic agonists combined with alkylamine-class H1-antihistamines used in ophthalmology.

Naphazoline + Pheniramine combines two complementary mechanisms of action in a single ophthalmic solution:

• Naphazoline is an imidazoline-derivative, direct-acting alpha-adrenergic agonist. Applied topically to the conjunctiva, it constricts superficial conjunctival blood vessels, reducing hyperemia (redness) within minutes of instillation.
• Pheniramine is a first-generation H1-receptor antagonist. It competitively blocks histamine at H1 receptors in ocular tissue, reducing itching, tearing, and allergic inflammation associated with allergic conjunctivitis.

Onset of decongestant action typically occurs within a few minutes and lasts several hours; the antihistamine effect helps control the allergic itch component during this time. Systemic absorption after topical ophthalmic use of Naphazoline + Pheniramine is normally minimal, but can be clinically significant in young children if the product is ingested.

To administer Napcon correctly:

• Wash hands before use. Tilt the head back and gently pull down the lower eyelid to form a small pocket.
• Instill the prescribed number of drops into the pocket without letting the dropper tip touch the eye, eyelid, fingers, or any other surface, to avoid contamination.
• Close the eye gently for 1–2 minutes and apply light pressure at the inner corner of the eye (near the nose) to reduce systemic absorption.
• Remove soft contact lenses before instilling Napcon and wait at least 10–15 minutes (or as advised by a physician) before reinserting them, unless the product is specifically labeled safe for use with contact lenses in place.
• Replace the cap tightly after use and keep the container out of reach of children.

Because Napcon is applied topically to the eye, clinically significant systemic drug interactions are uncommon, but the following should be noted:

• Monoamine oxidase inhibitors (MAOIs): Naphazoline, the sympathomimetic component of Napcon, may theoretically interact with MAOIs to cause a hypertensive reaction; concurrent use should be undertaken with caution.
• Other sympathomimetic agents (oral or ophthalmic decongestants, some nasal decongestants): Concurrent use with Napcon may have additive vasoconstrictive/pressor effects.
• Tricyclic antidepressants: May potentiate the pressor response to sympathomimetics such as the naphazoline component of Napcon.
• Other topical ophthalmic medications: If more than one eye medication is being used, space administration by at least 5–10 minutes to avoid dilution or washout of Napcon or the other product.

Most side effects of Napcon are local and transient. Reported adverse effects include:

• Transient stinging or burning sensation immediately after instillation.
• Temporary blurred vision or pupil dilation (mydriasis).
• Increased eye redness or irritation with overuse (rebound hyperemia/conjunctivitis medicamentosa) if used more frequently or longer than recommended.
• Increased intraocular pressure, particularly in susceptible individuals.
• Hypersensitivity reactions: eyelid swelling, itching, or allergic conjunctivitis to the product itself (uncommon).
• Headache, drowsiness, or dizziness (uncommon, related to the antihistamine component).

Discontinue Napcon and seek medical advice if severe or persistent reactions occur.

There are no well-controlled clinical studies establishing the safety of Napcon in pregnant or breastfeeding women. Although systemic absorption after ophthalmic use is generally low, Napcon should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

It is not known whether the components of Napcon pass into breast milk in clinically significant amounts. Caution is advised, and a physician or pharmacist should be consulted before using Napcon while breastfeeding.

The following precautions apply to the use of Napcon:

• For external ophthalmic use only; do not inject or swallow.
• Do not use Napcon for more than 72 hours continuously; overuse can cause rebound redness (conjunctivitis medicamentosa).
• Discontinue use and consult a physician if eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists beyond 72 hours.
• Not for use in patients with narrow-angle glaucoma (see Contraindications); use with caution in patients with any form of glaucoma, cardiovascular disease, hyperthyroidism, or diabetes mellitus, as the sympathomimetic component may rarely produce systemic effects.
• Remove contact lenses before use unless the product is labeled safe for use with lenses in place.
• Avoid touching the dropper tip to the eye or any surface to prevent contamination of the solution.
• Keep out of reach of children — accidental ingestion of Napcon by young children can cause serious systemic toxicity (see Overdose).
• Discard the solution if it changes color or becomes cloudy.

Ocular overuse: Using Napcon more often or for longer than recommended can cause rebound redness and worsening eye irritation.

Accidental ingestion: Napcon contains naphazoline, an imidazoline sympathomimetic that can cause serious systemic toxicity if the solution is swallowed, particularly by infants and young children. Symptoms of systemic overdose may include marked drowsiness or CNS depression, sweating, lowered body temperature, slow heart rate, low blood pressure, and even coma or respiratory depression in severe cases.

If accidental ingestion or a significant overdose of Napcon is suspected, seek immediate medical attention or contact a poison control center right away; do not attempt unsupervised home treatment.

Store Napcon at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed when not in use, discard the solution if it changes color or becomes cloudy, and keep out of reach of children.

• Elderly: No specific dose adjustment is established for Napcon in elderly patients, but they should be monitored for anticholinergic-type effects (e.g., blurred vision) and for cardiovascular sensitivity to the sympathomimetic component.
• Hepatic or renal impairment: Specific dose adjustment of Napcon has not been established; systemic absorption from ophthalmic use is minimal, so clinically significant accumulation is not generally expected, but caution is reasonable in severe impairment.
• Cardiovascular disease, hypertension, hyperthyroidism, diabetes mellitus: Use Napcon with caution, as the naphazoline component is a sympathomimetic that could theoretically produce systemic vasoconstrictor effects if significantly absorbed.
• Children: See Pediatric Uses.

Napcon should be used only for short-term, as-needed symptomatic relief and should not be used continuously for more than 72 hours (3 days). If symptoms persist, worsen, or recur after stopping treatment, a physician should be consulted before resuming use of Napcon.

Naphazoline + Pheniramine belongs to two combined drug classes: an ophthalmic decongestant (imidazoline-derivative, direct-acting alpha-adrenergic agonist — naphazoline) and a first-generation antihistamine (alkylamine-class H1-receptor antagonist — pheniramine).

Naphazoline + Pheniramine works through two complementary, locally acting mechanisms: the naphazoline component stimulates alpha-adrenergic receptors in conjunctival blood vessels, causing vasoconstriction and reducing visible redness; the pheniramine component blocks histamine H1-receptors in the conjunctiva, reducing itching, swelling, and allergic irritation. Together, these actions provide rapid, short-acting relief of the visible and symptomatic signs of allergic or irritative conjunctivitis.

Napcon is not recommended for children under 6 years of age unless specifically directed by a physician, as safety and efficacy in this age group have not been established under OTC labeling.

Young children are particularly vulnerable to systemic toxicity (marked CNS and cardiovascular depression) if the naphazoline component of Napcon is accidentally ingested, even in small amounts. The product should be kept well out of the reach of children, and any suspected ingestion requires immediate medical attention.

For children 6 years and older, the adult OTC dosing of Napcon may be used unless a physician advises otherwise.